The Rachel Fund for Myotonic Dystrophy
Muscular Dystrophy Canada and the Institute of Musculoskeletal Health and Arthritis are pleased to announce the third joint competition of the Rachel Fund. Launched originally in 2006, the Rachel Fund is proudly supported by Tribute Communities, a generous donor to Muscular Dystrophy Canada.
The objective of the Rachel Fund is to support research in one or both of the following themes:
- Research on therapeutics (pharmacological, cell based, genetic) and/or translational aspects that pertain directly to myotonic dystrophy;
- Research on the genetic, cellular or biochemical processes involved in myotonic dystrophy.
The total amount available for this funding opportunity is $300,000. The maximum amount awarded for a single grant is $100,000 per annum for up to 3 years. The competition will be administered as part of CIHR’s Winter 2013 Operating Grant, Priority Announcements. All applications must be submitted electronically using ResearchNet. How to apply?
Please note the following important dates:
| Registration | February 1, 2013 |
| Application deadline | March 1, 2013 |
| Anticipated Notice of Decision | June 28, 2013 |
| Funding start date | October 1, 2013 |
The CIHR-IMHA encourages researchers across disciplines within the arthritis, bone, skin, muscle, oral health and/or rehabilitation research communities, and across all four of CIHR research pillars, to develop research in areas covered by IMHA’s mandate and its flagship priority, physical activity, mobility and health, as these relate to myotonic dystrophy.
To apply or for more information:
Visit CIHR’s Funding Opportunities database, Operating Grants: Winter 2013 Priority Announcements Specific Research Areas
Select “Myotonic dystrophy (Rachel Fund)” under Section A: Priority Announcements and Relevant Research Area.
Note: To be considered for funding, you must remember to select the priority announcement title (i.e. Myotonic Dystrophy, Rachel Fund) in the “Identify Priority Announcements and Relevant Research Area” section of your ResearchNet application.
Questions? Please contact:
Marla Spiegel
National Director, Research
Muscular Dystrophy Canada
Telephone: 1-866-687-2538 ext 134
Email: Marla Spiegel
Tanya Gallant
Program Manager/Analyst
CIHR Institute of Musculoskeletal Health and Arthritis (IMHA)
Telephone: 613-954-3469
Email: Tanya Gallant
